Department of Emergency Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA.
Acad Emerg Med. 2021 Aug;28(8):859-865. doi: 10.1111/acem.14231. Epub 2021 Mar 12.
Use of oral opioids does not result in more pain relief than nonopioid alternatives when administered to patients as first-line treatment for acute musculoskeletal pain. This study compared the efficacy of oxycodone/acetaminophen to that of acetaminophen alone as second-line treatment for patients with acute musculoskeletal pain who were administered prescription-strength ibuprofen and reported insufficient relief 1 h later.
A randomized, double-blind study was conducted in two urban emergency departments. Opioid-naïve patients ≥ 18 years with an acute musculoskeletal injury were administered ibuprofen 600 mg as part of the study protocol. Those who reported insufficient relief 1 h later were randomized (1:1 ratio) to oxycodone 10 mg/acetaminophen 650 mg or acetaminophen 650 mg. The primary outcome was improvement in 0 to 10 pain scale between randomization and 2 h later. We also assessed medication-associated adverse events. A sample size calculation, built around a minimum clinically important difference of 1.3 units, determined the need for 154 patients.
We screened 924 patients and enrolled 393. All 393 received ibuprofen. A total of 159 (40%) patients reported inadequate relief after 1 h had elapsed. A total of 154 of these were randomized, 77 to oxycodone/acetaminophen and 77 to acetaminophen. Baseline characteristics were comparable. Among patients randomized to oxycodone/acetaminophen, mean (±SD) improvement in 0 to 10 pain scale was 4.0 (±2.6) versus 2.9 (±2.4) in the acetaminophen arm. The 95% confidence interval (CI) for the mean difference of 1.1 was 0.3 to 1.9. Among patients who received oxycodone/acetaminophen, 26 of 76 (34%) reported any medication-related adverse event versus seven of 74 (9%) participants who received acetaminophen. The 95% CI for the between-group difference of 25% was 12% to 37%).
Among patients with acute musculoskeletal pain refractory to oral ibuprofen, oxycodone/acetaminophen resulted in slightly greater pain relief than acetaminophen, but this was associated with more medication-related adverse events.
对于急性肌肉骨骼疼痛患者,作为一线治疗药物,与非阿片类药物替代物相比,口服阿片类药物并没有带来更多的疼痛缓解。本研究比较了羟考酮/对乙酰氨基酚与单纯对乙酰氨基酚作为一线治疗药物的疗效,这些药物用于接受处方强度布洛芬治疗后 1 小时报告疼痛缓解不足的急性肌肉骨骼疼痛患者。
在两个城市急诊部门进行了一项随机、双盲研究。纳入急性肌肉骨骼损伤且阿片类药物初治的年龄≥18 岁的患者,按照研究方案给予布洛芬 600mg。那些在 1 小时后报告疼痛缓解不足的患者随机(1:1 比例)接受羟考酮 10mg/对乙酰氨基酚 650mg 或对乙酰氨基酚 650mg。主要结局是随机分组至 2 小时时 0 到 10 疼痛评分的改善。我们还评估了与药物相关的不良事件。基于最小临床重要差异 1.3 个单位的样本量计算,确定需要纳入 154 例患者。
我们共筛查了 924 例患者,纳入了 393 例。所有 393 例患者均接受了布洛芬治疗。1 小时后共有 159 例(40%)患者报告疼痛缓解不足。其中 154 例患者随机分组,77 例接受羟考酮/对乙酰氨基酚治疗,77 例接受对乙酰氨基酚治疗。基线特征相似。在接受羟考酮/对乙酰氨基酚治疗的患者中,0 到 10 疼痛评分的平均(±标准差)改善为 4.0(±2.6),而在接受对乙酰氨基酚治疗的患者中为 2.9(±2.4)。95%置信区间(CI)为 1.1 的均值差值为 0.3 至 1.9。在接受羟考酮/对乙酰氨基酚治疗的患者中,26 例(34%)报告了任何与药物相关的不良事件,而接受对乙酰氨基酚治疗的患者中 7 例(9%)报告了任何与药物相关的不良事件。组间差异的 95%CI 为 25%,即 12%至 37%。
在对口服布洛芬疼痛缓解不足的急性肌肉骨骼疼痛患者中,羟考酮/对乙酰氨基酚比对乙酰氨基酚能稍微更有效地缓解疼痛,但这与更多的与药物相关的不良事件有关。